Novartis UK HCP Portal
Published on Novartis UK HCP Portal (https://www.health.novartis.co.uk)

Home > Printer-friendly > XOLAIR® (omalizumab)

Xolair® (omalizumab) [1]

This site contains information for UK healthcare professionals only on Xolair and chronic spontaneous urticaria.

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.1

 

*Post hoc analysis of phase 3 studies (ASTERIA I & II, and GLACIAL), demonstrated clinically meaningful improvements in quality of life (measured using DLQI) in patients with CSU.2

DLQI, Dermatology Life Quality Index; IgE, immunoglobulin E.

References

  1. Xolair® (omalizumab) 150 mg Summary of Product Characteristics.
  2. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.

Source URL: https://www.health.novartis.co.uk/medicines/dermatology/xolair

Links
[1] https://www.health.novartis.co.uk/medicines/dermatology/xolair